Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parkinson's patients get new hope: group therapy targets anxiety and depression

NCT ID NCT06992869

Symptom relief Sponsor: University College, London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three types of group psychological therapy for people with Parkinson's: one for adjusting to diagnosis, one for anxiety and depression, and one for memory and thinking problems. 138 participants took part, and the therapy was designed to be delivered by non-mental-health professionals. The goal was to see if it improves mood, quality of life, and coping, while also being cost-effective for the healthcare system.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
group-based psychological therapy
What this could lead to
If successful, this could provide a simple, low-cost mental health program for people with Parkinson's that can be delivered by non-specialists, improving quality of life and reducing hospital visits.
What could go wrong
This is a small pilot study (138 participants) with no control group, so results may not be generalizable. The therapy may not be effective for everyone, and long-term benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

138 people

The number who actually took part.

Started

Jul 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

All participants will be recruited from the National Hospital for Neurology and Neurosurgery, Queen Square, London. Inclusion Criteria: 1. Diagnosis of Parkinson's AND 1. within three years of diagnosis OR 2. anxiety/depression, as judged by scores above clinical cut-offs on standardized measures OR 3. developing Parkinson's-related cognitive impairment/hallucinations/delusions, but retaining capacity to consent, as judged by their medical consultant. 2. Aged 18 years and above 3. Sufficiently fluent in English 4. Able to give informed consent 5. Able to attend Queen Square for the intervention 6. Able to complete the self-report questionnaires Exclusion Criterion: * Already participating in psychological therapy or research aimed at improving psychological wellbeing.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson'S disease (PD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson'S disease (PD)

Contacts and locations

Locations

  • University College London

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.